Analysis of immune and high‐risk biomarkers in patients with relapsed or refractory mantle cell lymphoma treated with glofitamab monotherapy.

Autor: Pham*, T. H., Leung*, W., Hamidi, H., Dickinson, M., Morschhauser, F., Carlo‐Stella, C., Humphrey, K., Mulvihill, E., Lundberg, L., Filezac de L'Etang, A., Qayum, N., Bottos, A., Phillips, T.

Publikováno v: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p486-488, 3p

MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST‐LINE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): SAFETY AND EFFICACY REMAIN PROMISING WITH DURABLE COMPLETE RESPONSES.

Autor: Olszewski, A. J, Avigdor, A, Babu, S, Levi, I, Eradat, H, Abadi, U, Holmes, H, McKinney, M, Woszczyk, D, Giannopoulos, K, Jurczak, W, McCord, R, Xie, Y, Sarouei, K, Qayum, N, O'Hear, C, Sellam, G, Horowitz, N

Publikováno v: Hematological Oncology; Jun2021 Supplement S2, Vol. 39, p1-3, 3p

1050 poster CHANGES IN TUMOUR PERFUSION INDUCED BY NELFINAVIR AND RADIOTHERAPY: TRANSLATION TO A PHASE I-II CLINICAL TRIAL

Autor: Hill, E., Qayum, N., Brunner, T., Quirke, P., Mckenna, W., Sharma, R.A.

Publikováno v: In Radiotherapy and Oncology 2011 99 Supplement 1:S391-S391

ESTIMATION OF LONG‐TERM SURVIVAL WITH POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB FOR PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL).

Autor: Sehn, L.H., Flowers, C., McMillan, A., Morschhauser, F., Salles, G., Felizzi, F., Launonen, A., Qayum, N., Thuresson, P.O.

Publikováno v: Hematological Oncology; Jun2019 Supplement S2, Vol. 37, p257-258, 2p

Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study.

Autor: Phillips TJ; University of Michigan Medical School, Ann Arbor, MI.; Current address: City of Hope National Medical Center, Duarte, CA., Carlo-Stella C; Department of Biomedical Sciences, Humanitas University and IRCCS Humanitas Research Hospital, Milano, Italy., Morschhauser F; CHU Lille, Service des Maladies du Sang, Lille, France., Bachy E; Hospices Civils de Lyon and Université Claude Bernard, Pierre-Bénite, France., Crump M; Princess Margaret Cancer Centre, Toronto, ON, Canada., Trněný M; First Faculty of Medicine, Charles University, General Hospital, Prague, Czech Republic., Bartlett NL; Siteman Cancer Center, Washington University, St Louis, MO., Zaucha J; Medical University of Gdańsk, Gdańsk, Poland., Wrobel T; Wroclaw Medical University, Wroclaw, Poland., Offner F; Department of Hematology, Universitair Ziekenhuis, Gent, Belgium., Humphrey K; Roche Products Ltd, Welwyn Garden City, United Kingdom., Relf J; Roche Products Ltd, Welwyn Garden City, United Kingdom., Filézac de L'Etang A; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Carlile DJ; Roche Products Ltd, Welwyn Garden City, United Kingdom., Byrne B; Roche Products Ltd, Welwyn Garden City, United Kingdom., Qayum N; Roche Products Ltd, Welwyn Garden City, United Kingdom., Lundberg L; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Dickinson M; Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Oct 04, pp. JCO2302470. Date of Electronic Publication: 2024 Oct 04.